Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.62 |
| ▸ | CDK2 | P24941 | 12/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4362069 | 1.00 | AKT1 (0.62) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL4362073 | 1.00 | AKT1 (0.62) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL12064679 | 0.91 | AKT1 (0.64) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL4372108 | 0.89 | AKT1 (0.80) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL4372107 | 0.89 | AKT1 (0.80) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL4372104 | 0.89 | AKT1 (0.80) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL4294061 | 0.88 | AKT1 (0.79) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL4294051 | 0.88 | AKT1 (0.79) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL4294058 | 0.88 | AKT1 (0.79) | AKT1CDK2CDK1KITKDR | |
| SCHEMBL1742416 | 0.87 | AKT1 (0.67) | AKT1CDK2CDK1KITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | AKT1 143/4885CDK2 62/4885CDK1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.